Tavapadon

Sold as Juvmo. Every FDA application for this active ingredient.

First approved: Sep 25, 2026
Applications: 1
New uses approved: 0
Complete response letters: 0

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Sep 25, 2026	JuvmoNDA 220415 · New molecular entity	Abbvie	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.